Gracell Biotechnologies Receives IND Clearance For Phase 1 Trial Of GC012F In Multiple Myeloma

Written by Emily J. Thompson, Senior Investment Analyst

GRCL%

Source: Business Insider

Updated: Jan 29 2024

0mins

Source: Business Insider

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Gracell Biotechnologies Receives IND Clearance For Phase 1 Trial Of GC012F In Multiple Myeloma

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Davos Forum Highlights AI and Growth Opportunities

Société Générale Considers Relocating HQ, Scouting 500K Sq Ft in Manhattan

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch